ArticleFrontiers in oncology2025
METTL3-mediated SNHG1 m
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: As the most prevalent internal RNA modification in eukaryotic transcripts, N6-methyladenosine (m Methods: Bioinformatics analysis, RT-qPCR, western blotting assays were used to detect the expression of METTL3, SNHG1, RNA binding motif protein 15 (RBM15), WD repeat domain 74 (WDR74) and EWS RNA binding protein 1 (EWSR1) accordingly. Cell proliferation and motility ability changes were assessed by colony formation and transwell migration assays. RNA stability changes were evaluated by an Results: It was uncovered that METTL3 was significantly upregulated in OS tissues and cell lines. As an oncogenic regulator, METTL3 promoted proliferation and migration in OS cells by enhancing the stability of SNHG1. Mechanically, it was displayed that METTL3 catalyzed SNHG1 m6A modification with the assistance of RBM15. More deeply, it was found that SNHG1 promoted OS cells proliferation and migration via regulation of its neighboring gene WDR74. Meanwhile, it was discovered that SNHG1 affected WDR74 transcription by EWSR1 recruitment. Finally, it was displayed that overexpression of METTL3 promoted SNHG1 and WDR74 expression, and upregulation of METTL3 facilitated OS tumorigenesis and lung metastasis Conclusion: The present research illustrated that METTL3 enhanced the stability of SNHG1 with the assistance of RBM15 in an m6A dependent manner in OS cells. And SNHG1, promoted the transcription of WDR74 in cis, via recruitment of EWSR1, thereby facilitated WDR74-mediated proliferation and migration in OS cells. These findings provide new insights into the epigenetic regulation of OS and highlight potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.